Diabetic neuropathy. Effectiveness of amitriptyline and gabapentin;Neuropatía diabética. Eficacia de la amitriptilina y de la gabapentina

Revista de la Sociedad Espanola del Dolor

Volumn 11, Issue 8, 2004, Pages 490-504

  Vidal, M A ^a   Martinez Fernandez E ^b   Martinez Vazquez De Castro J ^c   Torres, L M ^c  

^a Serv Anestesiologia R   (Spain)

^b HOSPITAL DE JEREZ   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

Author keywords

Amitriptyline; Diabetic; Gabapentin; Neuropathic pain

Indexed keywords

AMITRIPTYLINE; GABAPENTIN;

ANTICHOLINERGIC EFFECT; DIABETIC NEPHROPATHY; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; HUMAN; INFORMATION RETRIEVAL; MEDLINE; PUBLICATION; REVIEW; RISK ASSESSMENT; SOMNOLENCE;

EID: 13944283753     PISSN: 11348046     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Tremont-Lukats I, Megeff C, Backonja M. Anticonvulsants for neuropathic pain syndromes. Mechanisms of action and place in therapy. Review article. Drugs 2000; 60: 1029-52.
2. Ahmad M, Roger C. Management strategies for the treatment of neuropathic pain in the elderly. Drugs Aging 2002; 19: 929-45.
3. Merskey H, Bog Duk N. Classification of chronic pain. 2nd ed. Seattle (WA): IASP Press, 1994.
4. Martínez A, Porta J, Berbel A, et al. Fármacos antiepilépticos y dolor neuropático. Rev Neurol 2001; 32: 345-50.
5. Backonja M. Anticonvulsants (antineuropathics) for neuropathic pain syndromes. Clin J Pain 2000; 16 (Supl.): S67-S72.
6. National Health & Medical Research Council. Acute pain management: scientific evidence. Australia: Commonwealth of Australia, 1999.
7. Galer B. Neuropathic pain of peripheral origin: advances in pharmacologic treatment. Neurology 1995; 45 (Supl. 9): S17-S25.
8. Ross EL. The evolving role of antiepileptic drugs in treating neuropathic pain. Neurology 2000; 55 (Supl. 1): S410-S46.
9. Hopton IL. Mes Resource 1997; 41: 159-62.
10. Bowsher D. Neurogenic pain syndrome and their management British Medical Bulletin 1991; 47: 644-66.
11. Verhaak PF, Kerssens JJ, Dekker J. Prevalence of chronic benign pain disorder among adults: a review of the literature. Pain 1998; 77: 231-9.
12. Isselbacher, Braunwald, Wilson. Principios de Medicina Interna. 13th ed. Madrid: Mc Graw-Hill Interamericana de España. 1994.
13. th ed. USA: W B Saunders Company, 1998.
14. Aguilar E, De Lugo B, Devesa J, et al. Tratado de endocrinología básica y clínica. Madrid: Editorial Síntesis SA, 2000.
15. Jensen P, Larson J. Management of painful diabetic neuropathy. Drugs and Aging 2001; 18: 737-49.
16. Joss JD. Tricyclic antidepressant use in diabetic neuropathy. Drug information rounds. The Annals of Pharmacotherapy 1999; 33: 996-1000.
17. Finegold D, Latimer SA, Nolle S, et al. Polyol pathway activity and myo-inositol metabolism: a suggested relationship in the pathogenesis of diabetic neuropathy. Diabetes 1983; 32: 988-92.
18. Greene DA, Stevens MJ, Feldman EL. Diabetic neuropathy: scope of the syndrome. Am J Med 1999; 107 (2B): 2S-8S.
19. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993; 328: 1676-85.
20. Parving H-H, Viberti GC, Keen H, et al. Hemodynamic factors in the genesis of diabetic microangiopathy. Metabolism 1983; 32: 943-9.
21. Winegrand AI. Does a common mechanism induce the diverse complications of diabetes? Banting lecture 1986. Diabetes 1986; 36: 396-406.
22. Greene DA, Lattimer SA, Sima AAF. Are disturbances of sorbitol, phosphoinositide, and Na+-K+-ATPase regulation involved in pathogenesis of diabetic neuropathy? Diabetes 1988; 37: 688-93.
23. Hillman N. Neuropatía diabética periférica. Medicine 2000; 19: 67-76.
24. Escobar F, Herrera JL. Actualizaciones clínicas y terapéuticas en la lesión nerviosa del diabético. Barcelona: Masson SA, 2000.
25. Boulton AJM, Jervell JA. Guidelines for the diagnosis and out-patient management od diabetic peripheral neuropathy. Diabetic Medicine 1998;15: 508-14.
26. Conget I, Esmatjes E, Gomis R. Patología vascular periférica en el diabético. Madrid: Edicomplet, 1996.
27. Wilbourn AJ. The diabetic neuropathies. In: Brown N, Bolton C, eds. Clinical electromyography. New York: Butterworths, 1983. p. 329-62.
28. Harris M, Eatsman R, Cowie C. Symptoms of sensory neuropathy in adults with NIDDM in the US population. Diabetes Care 1993; 16: 1446-52.
29. Tesfaye S, Stevens L, Stephenson J, et al. The prevalence of diavetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: The EURODIAB IDDM complications study. Diabetologia 1996; 39: 1377-84.
30. Cabezas-Cerrato J and the Spanish Diabetic Neuropathy Study Group. Multicentric and multiregional study of the prevalence of clinical diabetic peripheral neuropathy in Spain. 4th International Symposium of Diabetic Neuropathy. Amsterdam, 1997.
31. Pirart J. Diabetes Mellitus and its degenerative complications. A prospective study of 4400 patients observed between 1947 and 1973. Diabetes Care 1978; 1: 168-88, 252-63.
32. Rawn T, Papoushek C, Evans MF. Gabapentina or amitriptyline for painful diabetic neuropathy? Critical Appraisal Avaluation critique. Canadian Family Physician, 2000.
33. th ed. New York, N.Y.: Mc Graw-Hill, 1999. p. 1236-7.
34. Ellemberg M. Diabetes neuropathic caquexia. Diabetes; 1974; 23: 1-423.
35. Boulton AJM, Malk RA. Diabetic neuropathy. Med Clin North Am 1998; 82: 909-29.
36. Zleger D. Pharmacological treatment of painful diabetic neuropathy. In: Veves A, ed. Clinical management of diabetic neuropathy. Totawa, NJ: Humana Press 1998. p. 147-68.
37. Boulton AJM. Current and emerging treatments for the diabetic neuropathies. Diabetes Rev 1999; 7: 379-86.
38. Young MJ, Boulton AJ, Mac Leod AF, et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetología 1993; 36: 150-4.
39. Boulton AJM. Clinical management of the painful diabetic neuropathies. JR Coll Physicians Lond 2000; 34: 340-3.
40. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood/glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 32: 837-53.
41. Reichard P, Nilsson BY, Rosenquisit U. The effect of long-term intensified insulin treatment of microvascular complications of diabetes mellitus. N England J Med 1993; 329: 304-9.
42. The Diabetes control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N England J Med 1993; 329: 977-86.
43. Eastman RC, Sibert CW, Harris M, et al. Clinical review 51: implications of the diabetes control and complications trial. J Clin Endocrinol Metab 1993; 77: 1105-7.
44. Tamez HE, Forsbach G. Letter to the editor. Am J Med 2000; 108: 689.
45. Tesfaye S, Watt J, Benbow SJ, et al. Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. The Lancet 1996; 348: 1698-701.
46. Kupecz D. Treating painful diabetic neuropathy with gabapentin. The Nurse Practitioner 2001; 26: 10-3.
47. Vinik AL, Holland MT, Le Baeu JM. Diabetic neuropathies. Diabetes Care 1992; 15: 1924-74.
48. Carrington, Litchfield JE. The aldose reductase pathway and non-anzymatic glycation in the pathogenesis of diabetic neuropathy: a critical review for the end of the twentieth century. Diabetes Rev 1999; 7: 275-99.
49. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symtomatic diabetic neuropathy with the anti-oxidant a-lipolic acid; a 7-month randomised controlled trial. Diabetes Care 1999; 22: 1296-301.
50. Malk RA, Williamson S, Abbott CA. Effect of angiotensin-converting enzyme (ACE) inhibitor trandolaprilt on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998; 352: 1978-81.
51. Miki S, Yoshinaga N, Iwamoto T, et al. Antinociceptive effect of the novel OT-7100 in a diabetic neuropathy model. Europan Journal of Pharmacology 2001; 430: 229-34.
52. Courteix C, Eschalier A, Lavarenne J. Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain 1993; 53: 81-8.
53. Hotta N, Sakamoto N, Shigeta N, et al. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy on Japan. J Diabetes Complications 1996; 10: 168-72.
54. Kikkawa R, Hatanaka I, Yasuda H, et al. Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-((2E)-methyl-3-phenylpropenylidene) rhodaine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats. Diabetologia 1983; 24: 290-2.
55. Pfeifer MA, Schumer MP, Gelber D. Aldose reductase inhibitors: the end of a era or the need for diferent trial designs? Diabetes 1997; 46 (Supl. 2): S82-S89.
56. Liniger C, Pernet A, Moody JF, et al. Effect of gangliosides on diabetic perpheral neuropathy. Diabetes Res Clin Pract 1989; 7: 251-8.
57. Y-linolenic Acid Multicenter Trial Group. Treatment of diabetic neuropathy with Y-linolenic acid. Diabetes Care 1993; 16: 8-15.
58. Cameron NE, Cotter MA, Robertson S. Angiotensin converting enzyme inhibition prevents development of acetyl-carnitine for symtomatic diabetic neuropathy. Diabetologia 1995; 38: 123.
59. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant a-lipolic acid: a 3-week multicentre randomized control trial (ALADIN Study). Diabetologia 1995; 38: 1425-33.
60. Yagishashi S, Kamijo M, Baba M, et al. Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 1992; 41: 47-52.
61. Verma A, Bradley WG. High-dose intravenous inmunoglobulin therapy in chronic progressive lumbosacral lexopathy. Neurology 1994; 44: 248-50.
62. Pfeifer MA, Ross DR, Schrage JP, et al. A highly successful and novel model for treatment of chronic painful diabetic peripheral neuropathy. Diabetes Care 1993; 16: 1103-15.
63. Kumar D, Alvaro MS, Julka IS, et al. Diabetic peripheral neuropathy: effectiveness of electrotherapy: and amitriptyline for symtomatic relief. Diabetes Care 1998; 21: 1322-5.
64. Kumar D, Marshall HJ. Diabetic peripheral neuropathy: amelioration of pain with transcutaneous electrostimulation. Diabetes Care 1997; 20: 1702-5.
65. Long DM, Erickson D, Campbell J, et al. Electrical stimulation of the spinal cord and peripheral nerves for pain control-10 years' experience. Appl Neurophysiol 1981; 44: 207-17.
66. th ed. Baltimore: William and Wilkins, 1988.
67. Long DM, Erickson DE. Stimulation of the posterior columns of the spinal cord for the relief of intractable pain. Surg Neurol 1975; 4: 134-41.
68. Benbow SJ, Chan AW, Bowsher D, et al. Prospective study of painful symptoms, small-fibre function and peripheral vascular disease in chronic painful diabetic neuropathy. Diabetic Med 1994; 11: 17-21.
69. Boulton AJM. The pathogenesis of diabetic foot problems an overview. Diabetic Med 1996; 13 (Supl. 1): S12-S16.
70. Backonja M. Gabapentin monotherapy for the symtomatic treatment of painful neuropathy: A multicenter, double-blind, placebo-controlled trial in patients With Diabetes Mellitus. Epilepsia 1999; 40 (Supl. 6): S57-S59.
71. Dallocchio C, Buffa C, Mazzarello P, et al. Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open- label pilot study. J Pain Symtom Manage 2000; 20: 280-5.
72. Low PA, Dotson RM. Sympomatic treatment of painful neuropathy. JAMA 1998; 280: 1863-4.
73. Young RJ, Clarke BP. Painful relief in diabetic neuropathy: The effectiveness of imipramine and related drugs. Diabetic Med 1985; 2: 263-366.
74. Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal and depressed mood. Neurology 1987; 37: 589-96.
75. Bryson HM, Wilde MI. Amitrptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Drugs & Aging 1996; 8: 459-76.
76. Biesbroeck R, Bril V, Hollander P, et al. A double-blind comparison of topical capsaicin and oral amitriptyline in painful diabetic neuropathy. Adv Ther 1995; 12: 111-20.
77. MCQuay HJ, Tramer M, Nye BA, et al. A systematic review of antidepressants in neuropathic pain. Pain 1996; 68: 217-27.
78. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. New Engl J Med 1992; 326: 1250-6.
79. Turkington RV. Depression masquerading us diabetic neuropathy. JAMA 1980; 21: 243: 1147-50.
80. Vrethem M, Boivie J, Arnqvist H, et al. A coparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and non-diabetics. Clinical Journal Pain 1997; 13: 313-23.
81. Davis P. Nonepiletic uses of gabapentin. Epilepsia 1999; 40 (Supl. 6): S66-S72.
82. Caviedes BE, Herranz JL. Uso de los fármacos antiepilé pticos en trastornos no epilépticos. Rev Neurol 2001; 33: 241-9.
83. th ed. Toronto: Mc Graw-Hill, 1992. p. 436-462.
84. Package insert. Neurontin (gabapentine). Morris Pains NJ.: Parke-Davis Pharmaceuticals, 2000.
85. Blanco MA, López MI, Serrano M. La gabapentina en el tratamiento del dolor neuropático. Rev Soc Esp del Dolor 1998; 5 (Supl. 1).
86. Bartoszyk GD, Fritschi E, Hermann M. Indications for an involvement of the GABA-system in the mechanism of actino of gabapentin. Naunyn Schmiedebergs Arch Pharmacol 1983; 322 (Supl.): R94.
87. Satzinger G. Antiepileptics from gamma- aminobutyric acid. Arzneimittelforschung 1994; 44: 261-6.
88. Taylor CP. Gabapentin: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. New York: Raven Press, 1995. p. 829-41.
89. Taylor CP. Mechanisms of action of gabapentin. Rev Neurol 1997; 153: S39-S45.
90. Mc Namara J. Drugaacting on the central nervous system. In: Harman G, Limbird LE, Morinoff PB, EAL, eds. Goodman's and Gilman's the pharmacological basis of therapeutics. New York: Mc Graw-Hill, 1996. p.461-86.
91. Jensen TS. Anticonvulsants in neuropathic pain. Eur J Pain 2002; Supl. A: 61-8.
92. Perucca E. The clinical pharmacokinetics of the new antiepileptic drugs. Epilepsia 1999; 40 (Supl. 9): S7-S13.
93. Gatti G, Bonomi I, Januzzi G, et al. The new antiepileptic drugs: pharmacological and clinical aspects. Current Pharmaceutical Design 2000; 6: 839-60.
94. Gorson KC, Schott C, Herman R, et al. Gabapentin in the treatment of painful diabetic neuropathy. A placebo controlled double-blind, crossover trial. J Neurol Neurosurg Psychiatry 1998; 62: 251-2.
95. Morello CM, Leckbrand SG, Stoner CP. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999; 159: 1931-7.
96. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999; 83: 389-400.